Trial Profile
A Phase 2 Study of the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Multiple Doses of TD-4208 for 7 Days in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Revefenacin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Mylan Pharmaceuticals Inc.; Theravance; Theravance Biopharma
- 29 Oct 2020 Results of pooled analysis of data pooled from three phase II and two phase III studies (NCT03064113, NCT01704404, NCT02040792, NCT02459080, and NCT02512510) assessing the pharmacokinetics of Revefenacin and its major metabolite, published in the Clinical Pharmacokinetics
- 08 Sep 2014 Pharmacokinetic results presented at the 24th Annual Congress of the European Respiratory Society.
- 23 Jan 2014 According to ClinicalTrials.gov, status changed from active, no longer recruiting to completed.